Comparison of Serum Human Epididymis Protein 4 and Carbohydrate Antigen 125 as Markers in Endometrial Cancer: A Meta-Analysis

International Journal of Gynecological Cancer

Volumn 26, Issue 2, 2016, Pages 331-340

  Hu, Lingli ^a   Du, Shizheng ^b   Guo, Wanhua ^a   Chen, Dezhu ^a   Li, Ying ^c  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^c AFFILIATED ZHONGDA HOSPITAL OF SOUTHEAST UNIVERSITY   (China)

Author keywords

Carbohydrate antigen 125; Diagnostic test; Endometrial cancer; Meta analysis; Serum human epididymis protein 4

Indexed keywords

CA 125 ANTIGEN; HUMAN EPIDIDYMIS PROTEIN 4; MEMBRANE PROTEIN; MUC16 PROTEIN, HUMAN; PROTEIN; WFDC2 PROTEIN, HUMAN;

ARTICLE; CANCER SCREENING; COMPARATIVE STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ENDOMETRIUM CANCER; HUMAN; META ANALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; BLOOD; ENDOMETRIUM TUMOR; FEMALE; METABOLISM;

CA-125 ANTIGEN; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MEMBRANE PROTEINS; PROTEINS;

EID: 84957538329     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0000000000000621     Document Type: Article

References (43)

1. World Health Organization. GLOBOCAN 2012: Estimated Cancer incidence, Mortality, and Prevalence Worldwide in 2012. Available at http://globocan.iarc.fr/Default.aspx. Accessed May 17, 2015.
2. Lajer H, Elnegaard S, Christensen RD, Survival after stage IA endometrial cancer; can follow-up be altered? A prospective nationwide Danish survey. Acta Obstet Gynecol Scand. 2012; 91: 976-982. doi: 10.1111/j.1600-0412.2012.01438.x.
3. Aggarwal P, Kehoe S,. Serum tumour markers in gynaecological cancers. Maturitas. 2010; 67: 46-53. doi: 10.1016/j.maturitas.2010.04.017.
4. Kirchhoff C, Habben I, Ivell R, A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors. Biol Reprod. 1991; 45: 350-357.
5. Zhen S, Bian LH, Chang LL, Comparison of serum human epididymis protein 4 and carbohydrate antigen 125 as markers in ovarian cancer: a meta-analysis. Mol Clin Oncol. 2014; 2: 559-566.
6. Lin J, Qin J, Sangvatanakul V,. Human epididymis protein 4 for differential diagnosis between benign gynecologic disease and ovarian cancer: a systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2013; 167: 81-85. doi: 10.1016/j.ejogrb.2012.10.036.
7. Ferraro S, Braga F, Lanzoni M, Serum human epididymis protein 4 vs carbohydrate antigen 125 for ovarian cancer diagnosis: a systematic review. J Clin Pathol. 2013; 66: 273-281. doi: 10.1136/jclinpath-2012-201031.
8. Lin JY, Qin JB, Li XY, Diagnostic value of human epididymis protein 4 compared with mesothelin for ovarian cancer: a systematic review and meta-analysis. Asian Pac J Cancer Prev. 2012; 13: 5427-5432.
9. Cheng D, Sun Y, He H,. The diagnostic accuracy of HE4 in lung cancer: a meta-analysis. Dis Markers. 2015; 2015: 352670. doi: 10.1155/2015/352670.
10. Bie Y, Zhang Z,. Diagnostic value of serum HE4 in endometrial cancer: a meta-analysis. World J Surg Oncol. 2014; 12: 169. doi: 10.1186/1477-7819-12-169.
11. Zhang J, Wang YJ, Huo LJ, Human epididymis protein 4 in early diagnosis of endometrial cancer: a systematic review. Chin J Evid-based Med. 2014; 14: 72-78.
12. Whiting PF, Rutjes AW, Westwood ME, QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011; 155: 529-536. doi: 10.7326/0003-4819-155-8-201110180-00009.
13. Devillé WL, Buntinx F, Bouter LM, Conducting systematic reviews of diagnostic studies: didactic guidelines. BMC Med Res Methodol. 2002; 2: 9.
14. Higgins JPT, Green S, (editors). the Cochrane Collaboration, 2011. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane collaboration. Available at: http://handbook.cochrane.org/. Accessed April 20, 2015.
15. Moore RG, Brown AK, Miller MC, Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol Oncol. 2008; 110: 196-201. doi: 10.1016/j.ygyno.2008.04.002.
16. Bignotti E, Ragnoli M, Zanotti L, Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients. Br J Cancer. 2011; 104: 1418-1425. doi: 10.1038/bjc.2011.109.
17. Cong PS, Sun GR, Zhang NN, Evaluation on the value of human epididymis protein 4 in the early diagnosis of endometrial and ovarian cancers. Lab Med. 2011; 26: 447-451.
18. Ma R, Geng XX, Tang LP, Clinical significance of detecting serum human epididymis secretory protein 4 in the diagnosis and prognosis of endometrial cancer. Chin Clin Oncol. 2011; 16: 790-793.
19. Wu F, Zhou HQ, Cui MH,. Clinical value of combined detection of CA125 and HE4 in diagnosis of endometrial carcinoma. Chin J Gynecol Pediatr Care. 2011; 26: 1559-1561.
20. Yang SH, Li Q,. The Expression of HE4 in Serum of Patients With Endometrial Carcinoma and the Clinical Value of Combined Detection With CA125. (masteral dissertation). Bengbu, Anhui Province, China: Bengbu Medical College; 2011.
21. Jian HQ, Xu CL,. Urine Human Epididymis Protein 4 (HE4) as a Biomarker for the Diagnosis and the Differential Diagnosis of Ovarian and Endometrial Carcinomas. (masteral dissertation). Shijiazhuang, Hebei Province, China: Hebei Medical University; 2012.
22. Zanotti L, Bignotti E, Calza S, Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcome. Clin Chem Lab Med. 2012; 50: 2189-2198.
23. Zhang AM, Zhang P,. Clinical value of combined detection of serum human epididymal secretory protein E4 and CA(125) in the diagnosis of endometrial carcinoma. Zhonghua Fu Chan Ke Za Zhi. 2012; 47: 125-128.
24. Zhang SG,. Research of tumor markers for endometrial cancer risk evaluation. J Int Obstet Gynecol. 2013; 40: 466-469.
25. Zhao LQ, Chen X, Chen L, Differential diagnostic value of combined detection of serum HE4 and CA125 in patients with endometrial carcinoma from benign uterus tumor. China Oncol. 2012; 22: 820-824.
26. Angioli R, Plotti F, Capriglione S, The role of novel biomarker HE4 in endometrial cancer: a case control prospective study. Tumour Biol. 2013; 34: 571-576. doi: 10.1007/s13277-012-0583-0.
27. Antonsen SL, Høgdall E, Christensen IJ, HE4 and CA125 levels in the preoperative assessment of endometrial cancer patients: a prospective multicenter study (ENDOMET). Acta Obstet Gynecol Scand. 2013; 92: 1313-1322. doi: 10.1111/aogs.12235.
28. Omer B, Genc S, Takmaz O, The diagnostic role of human epididymis protein 4 and serum amyloid-A in early-stage endometrial cancer patients. Tumour Biol. 2013; 34: 2645-2650. doi: 10.1007/s13277-013-0814-z.
29. Yu WQ, Hong LQ, Liu ZF,. The clinical value of serum HE4 in diagnosis of ovarian tumor and endometrial carcinoma. Chin J Health Lab Tech. 2013; 23: 416-419.
30. Lin YY, Chen Y, Hu MH, Clinical value of serum HE4, CA125 and CA199 in combination or alone in the preoperative diagnosis of endometrial carcinoma. Chin J Clin Lab Sci. 2014; 32: 471-473.
31. Lin YY, Chen Y, Hu MH, Diagnostic and prognostic value of serum HE4 detection for endometrial carcinoma patients compared with CA 125. Curr Immunol. 2014; 34: 47-51.
32. Pan ZV, Ding JW, Wang KY, Combined diagnostic value of serum human epididymis protein 4, CA125 and CA19-9 in endometrial carcinoma patients. Chin J Health Lab Tech. 2014; 24: 1600-1603.
33. Presl J, Novotny Z, Topolcan O, CA125 and HE4 levels in a Czech female population diagnosed with endometrial cancer in preoperative management. Anticancer Res. 2014; 34: 327-331.
34. Sun SM, Xiao XC, Zhang DF,. Clinical value of combined detection of CA125 and HE4 in diagnosis of endometrial carcinoma. Heilongjiang Med Pharm. 2014; 37: 2-3.
35. Liu X, Zhao F, Hu L, Value of detection of serum human epididymis secretory protein 4 and carbohydrate antigen 125 in diagnosis of early endometrial cancer of different pathological subtypes. Oncol Targets Ther. 2015; 8: 1239-1243. doi: 10.2147/OTT.S81853.
36. Zhang J, Xu Z, Li K,. Evaluation on the effect index of diagnostic test. Chin J Evid-based Med. 2013; 13: 890-895.
37. Moore RG, Bast RC Jr,. How do you distinguish a malignant pelvic mass from a benign pelvic mass? Imaging, biomarkers, or none of the above. J Clin Oncol. 2007; 25: 4159-4161.
38. Drapkin R, von Horsten HH, Lin Y, Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. 2005; 65: 2162-2169.
39. Galgano MT, Hampton GM, Frierson HF Jr,. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol. 2006; 19: 847-853.
40. Moss EL, Hollingworth J, Reynolds TM,. The role of CA125 in clinical practice. J Clin Pathol. 2005; 58: 308-312.
41. Chen SL, Wu YS,. Development of a Dual-Label Time-Resolved Fluoroimmunoassay for the Detection of Human Epididymis Secretory Protein 4 (HE4) and Cancer Antigen 125 (CA125). (masteral dissertation). Guangzhou, China: Southern Medical University; 2014: 9.
42. Wang HR, Wang HN, Mo LZ,. The clinical application of CA125 and HE4 in endometrial cancer. Chin J Oncol Prev Treat. 2014; 6: 198-201.
43. Nagy B Jr, Krasznai ZT, Balla H, Elevated human epididymis protein 4 concentrations in chronic kidney disease. Ann Clin Biochem. 2012; 49: 377-380. doi: 10.1258/acb.2011.011258.